Parse Biosciences Announces Evercode TCR and Gene Capture
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
HOLLYWOOD, Fla. -- Businesswire -- Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Evercode™ TCR and Gene Capture. These new solutions expand the Parse Biosciences portfolio to address higher scale and immune profiling applications.
Evercode TCR provides researchers the ability to profile T cell receptors (TCR) together with whole transcriptomes in single cells at scale. The diversity of possible TCRs in the immune repertoire is enormous, yet the low throughput of existing tools have limited the ability to capture this complexity at high resolution. Evercode TCR will enable researchers to measure whole transcriptomes and paired TCR sequences - both alpha and beta chains - in up to 1 million cells. Combining TCR sequences with gene expression at this scale makes it possible to track TCR clonotypes across different T cell subtypes and activation states to understand the immune repertoire at exceptional resolution.
Parse also announced the launch of Gene Capture, a solution to reduce sequencing needs for larger studies. Gene Capture focuses sequencing on the most relevant genes, making it possible to efficiently scale projects to millions of cells and hundreds of samples. The solution allows researchers to enrich for 100s-1000s of genes, requiring 10 times less sequencing. Researchers can order a predesigned panel of approximately 1,000 genes relevant to immunology, the Immune1000, or design a panel unique to their needs.
“Increasingly, we see the need to support larger single cell RNA sequencing studies. Biology is complex and requires robust studies across multiple samples, timepoints, and many individual cells to fully capture this complexity,” notes Parse co-founder and CEO Alex Rosenberg, Ph.D. “Parse’s technology has already brought unprecedented scale to the market, and these new tools will expand these capabilities, unlocking new applications in both the research and translational space.”
Charles Roco, Ph.D., Parse co-founder and CTO, will present on the capabilities of Parse’s Evercode TCR and Gene Capture products at the AGBT General Meeting this week at his session, “Broadening Access to Scalable Single Cell Sequencing,” on Wednesday, February 8 at 3:35 pm in the Grand Ballroom.
To learn more about Evercode TCR and Gene Capture Enrichment, please visit www.parsebiosciences.com.
About Parse Biosciences
Parse Biosciences is a Seattle-based company with the mission of accelerating progress in human health and scientific research. At the core of our company is our pioneering approach for single cell sequencing. Single cell sequencing has already enabled groundbreaking discoveries which have led to new understandings of cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. At Parse Biosciences, we are providing researchers with the ability to perform single cell sequencing with unprecedented scale and ease. To learn more, please visit https://www.parsebiosciences.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005617/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Parse Biosciences
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 기아, 더 뉴 EV6 티저 이미지 공개 - 뉴스와이어
- ‘난타’의 송승환 감독, 한국형 에든버러 축제 만든다 - 뉴스와이어
- LS일렉트릭, 미래 주도할 친환경 스마트 전력 솔루션 총출동 - 뉴스와이어
- 마이원픽, K-POP SEOUL과 업무 협약 체결… 서울가요대상 월간투표 공동 진행 - 뉴스와이어
- 이니스프리, 최대 70% 할인 ‘5월 슈퍼 빅세일’ 시작 - 뉴스와이어
- 원더쉐어, 가정의 달 맞아 쉬운 영상 편집 프로그램 ‘필모라’ 이벤트 진행 - 뉴스와이어
- ‘마음:단단’ 앱, 어르신을 돌보는 사람들을 위한 무료 심리상담 지원 - 뉴스와이어
- 서울대 공대 전기정보공학부 곽정훈 교수팀, 차세대 양자점 저항변화 메모리의 스위칭 메커니즘
- 무지방·고단백 설계, 매일유업 ‘매일 바이오 프로틴 요거트’ 출시 - 뉴스와이어
- 삼성SDS, 생성형 AI 서비스 ‘FabriX 및 Brity Copilot’ 출시 - 뉴스와이어